Harnessing Tumor Organoids to Revolutionize Immunotherapy Research

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immunotherapy represents a significant advancement in cancer treatment.
• Current preclinical models lack the complexity to fully evaluate immunotherapy efficacy.
• Tumor organoids offer a more accurate recapitulation of patient tumors and their microenvironments.

Purpose of the Study:

• To systematically review methodologies for constructing tumor microenvironment (TME)-simulating organoids.
• To examine the applications and challenges of organoid technology in immunotherapy research.
• To explore the potential of organoids as a predictive platform for immunotherapy efficacy.

Main Methods:

• Review of current methodologies for building TME-simulating organoids.
• Analysis of organoid applications in various immunotherapy strategies (e.g., immune checkpoint inhibitors, cell immunotherapy, cancer vaccines).
• Evaluation of organoid advantages and limitations in preclinical immunotherapy studies.

Main Results:

• Organoids faithfully recapitulate histological, genetic, and phenotypic tumor characteristics.
• Complex organoid models can integrate immune cells and other TME components.
• Organoid technology shows potential for predicting immunotherapy response.

Conclusions:

• Organoid technology provides a powerful tool for advancing cancer immunotherapy research.
• Organoids can serve as a novel platform for the predictive evaluation of immunotherapy efficacy.
• Further development of organoid models is crucial for enhancing therapeutic outcomes in cancer patients.